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srecent workshop sponsored by the European Commission
dentified atherothrombosis as among the top current pri-
rities for translational research in cardiovascular disease (1).
n the present review, we summarize significant advances
uring the past year in this field. Major journals in cardi-
logy and internal medicine published in English were
arefully searched, selecting relevant studies in 4 categories:
pidemiology, mechanisms of disease, early detection and
isk stratification, and prevention and treatment.
pidemiology
ecent improvements in survival related to coronary heart
isease (CHD) can be partly explained by reductions in risk
actors in the population. Despite overall positive trends,
articularly in dyslipidemia and smoking, a comparison of 4
HANES (National Health and Nutrition Examination
urveys) indicated that in the past decade, the prevalence of
ow risk factor burden has decreased, with increases in blood
ressure levels and obesity (2). Risk profile and the inci-
ence of myocardial infarction may have particularly wors-
ned among middle-aged women (3). Type 2 diabetes
ncreased not only in the industrialized world but also in
eveloping countries (4). Similar discouraging results came
rom the EUROASPIRE (European Action on Secondary
revention Through Intervention to Reduce Events) survey
n 8 European countries (5). Despite improvements in lipid
ontrol, no significant changes in blood pressure levels or
moking were obtained, and increases in obesity and diabe-
es were seen in patients with established CHD (Fig. 1).
Several studies addressed the importance of cardiovascu-
ar risk factors at an early age. A prospective study in 20
uropean countries predicted a doubling of incident cases of
ype 1 diabetes in children before 2020 (6). Dyslipidemia
uring adolescence, particularly in combination with obe-
ity, was associated with future subclinical atherosclerosis as
etermined by the carotid intima-media thickness (CIMT)
7). In 10-year-old children, tobacco exposure was corre-
ated with low-grade inflammation and altered lipid metab-
rom *The Zena and Michael A. Wiener Cardiovascular Institute/Marie-Josee and
enry R. Kravis Center for Cardiovascular Health, Mount Sinai School of Medicine,
ew York, New York; and †Centro Nacional de Investigaciones Cardiovasculares,p
adrid, Spain.
Manuscript received December 2, 2009; accepted December 7, 2009.lism (8). Moreover, fetal exposure to parental smoking
eads to higher CIMT during youth (9).
echanisms of Disease
he progression of atherosclerosis from early development
o plaque rupture was viewed as the failure of 3 main defense
echanisms (endothelial progenitor cells, plaque neovascu-
arization, and reverse cholesterol transport) to counteract
ontinuous aggression to the vessel wall, and the promotion
f these mechanisms was proposed as an approach to
reserve vascular health (10). The second defense mecha-
ism received special attention in 2009. Plaque neovascu-
arization constitutes a response to tissue hypoxia and
holesterol deposition in the vessel wall. A potential regu-
atory effect on angiogenesis of the atheroprotective adipo-
ine adiponectin was described (11). A detailed electron
icroscopy study revealed that coronary neovessels contain
ndothelial cells of abnormal morphology, aberrant gap
unctions, and leukocyte adherence (12). This leads to
ncreased permeability that precipitates intraplaque hemor-
hage, with deleterious effects of extracorpuscular hemoglo-
in (10). On a protective basis, haptoglobin counteracts the
edox activity of hemoglobin, and the haptoglobin genotype
-2 was shown to be the major determinant of the amount
f redox active iron in the plaque (13). The presence of
ntraplaque bleeding also promotes macrophage recruitment
nd activation, which in turn causes a release of proteinases
nd favors plaque rupture. A novel atheroprotective
emorrhage-associated macrophage population was de-
cribed, defined by high levels of scavenger receptor CD163
nd high iron content, and promoted by interleukin 10 (14).
nalysis of human coronary endarterectomy samples
howed enhanced expression of CD163 and interleukin 10
n plaques from patients with acute coronary syndromes
15). Heme oxygenase-1 is an intracellular enzyme that
egrades free heme into ferrous iron, which is rapidly
equestered by ferritin. Heme oxygenase-1 gene expres-
ion was found to be increased in human plaques from
atients with diabetes (16). On a different topic, the
resence of cholesterol crystals was strongly associated
ith plaque rupture, thrombus, symptoms, and plaque
ize and was proposed as a mechanical contributor to
laque disruption (17).
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onventional risk factors. Long-term follow-up of the Fra-
ingham Offspring cohort (18) allowed the derivation of
0-year risk equations for hard and overall cardiovascular events
hat provide substantial additional information in comparison
ith 10-year estimates (Fig. 2). A unified definition for the
etabolic syndrome (Table 1) was also proposed in an attempt to
void previous discrepancies (19).
The optimal lipid fraction for proper risk stratification
ontinued to be discussed. The apolipoprotein B/apoli-
oprotein A-I ratio outperformed standard lipid mea-
urements in predicting cardiovascular mortality in 7,594
dults from NHANES III, although it was not better
Figure 1 European Trends in Risk Factor Control
The 12-year trends in risk factor control in Europe in patients with established cor
EUROASPIRE  European Action on Secondary Prevention Through Intervention to
Figure 2 Short- Versus Long-Term Cardiovascular Risk
Ten- versus 30-year risk of hard cardiovascular disease events in a 45-year-old wo
and man (B) with different risk factors profiles. Modified, with permission, from Pehan apolipoprotein B alone (20). Conversely, conven-
ional cholesterol measurements were as predictive of
ortality as apolipoprotein concentrations in 5,096 pa-
ients with CHD (21). A U-shaped relationship between
ody mass index and total and cardiovascular mortality
as reported in a combined analysis of studies including
lmost 900,000 participants (22). In addition, data from
large prospective cohort indicated additive value of
ndexes of overall adiposity (such as waist circumference
r the waist/hip ratio) to body mass index in predicting
urvival (23). Regarding the impact of pollution, one
nvestigation of 9 million elderly subjects demonstrated
n association between short-term exposure to ambient
arbon monoxide and risk for cardiovascular disease
eart disease.
e Events. Data from Kotseva et al. (5).
)
et al. (18).onary h
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April 6, 2010:1487–98 Year in Atherothrombosisospitalization, even at very low levels well below current
egulatory standards (24).
unctional biomarkers. Functional markers of subclinical
isease showed additive predictive value over conventional
isk factors. Endothelial dysfunction as determined by
bnormal flow-mediated vasodilation was associated with
-year incident cardiovascular events in apparently healthy
articipants in the MESA (Multi-Ethnic Study of Athero-
clerosis). It led to a net reclassification improvement (the
roportion of patients whose risk is correctly reclassified) of
9% compared with the Framingham risk score (25). Not
nly the presence but also the progression of peripheral
rterial disease (defined as a decline in the ankle-brachial
ndex 0.15 over 5 years) was independently associated
ith increased cardiovascular risk (26).
erum biomarkers. The use of novel biomarkers for prog-
ostic stratification in apparently healthy subjects was re-
orted to increase net reclassification improvement, partic-
larly if restricted to the intermediate-risk subjects (27).
eyond their implications for patient management (see the
ollowing discussion), the roles of inflammation in athero-
enesis and risk assessment continued to be a matter of
ebate. It was shown in animal models that inflammation
auses impairment in reverse cholesterol transport (28). In
ddition, a study demonstrated that human circulating
-reactive protein (CRP) can be dissociated by activated
latelets into a proinflammatory form that deposits in
therosclerotic plaques (29). However, large genomewide
ssociation studies continued to argue against a relevant
ausal role of CRP in CHD (30). The potential role of CRP
n guiding therapy was addressed in the JUPITER (Justifi-
ation for the Use of Statins in Primary Prevention: An
ntervention Trial Evaluating Rosuvastatin) study (see the
ollowing discussion). Data from the Dallas Heart Study
dentified independent associations of endothelial cell–
elective adhesion molecule and burden of atherosclerosis
hat were not observed for other adhesion molecules (31). In
ddition, statin-associated decrease in peripheral monocyte
ount was proposed as a novel marker of coronary athero-
clerotic regression (32).
A meta-analysis of 36 prospective studies confirmed
ignificant although modest independent associations be-
nified Definition of the Metabolic SyndromeTable 1 Unified Definition of the Metabolic Syndrome
Marker Cut Points
Elevated waist circumference Population- and country-specific definitions
Elevated triglycerides
(or drug therapy for it)
150 mg/dl
Reduced HDL cholesterol
(or drug therapy for it)
40 mg/dl in men; 50 mg/dl in women
Elevated blood pressure
(or drug therapy for it)
Systolic 130 mm Hg and/or
diastolic 85 mm Hg
Elevated fasting glucose
(or drug therapy for it)
100 mg/dl
odified from Alberti et al. (19).
HDL  high-density lipoprotein.ween lipoprotein(a) and incident myocardial infarction and otroke (33). Besides its known prothrombotic effects, an-
ther potential deleterious role of this biomarker may be as
carrier of proinflammatory oxidized low-density lipopro-
ein (LDL) cholesterol (34). The possible influence of
ltered calcium-phosphate metabolism in cardiovascular risk
as addressed in different studies. Low vitamin D levels,
hich may lead to secondary hyperparathyroidism, were
ound in approximately 75% of U.S. adults with cardiovas-
ular disease (35). A potential mechanism for these findings
as described: vitamin D inhibited macrophage transfor-
ation into foam cells in patients with diabetes (36). High
oncentrations of parathyroid hormone were related to
ardiovascular mortality in elderly men beyond vitamin D
evels or other markers of mineral metabolism (37). Simi-
arly, elevated levels of alkaline phosphatase, perhaps acting
s a mediator of vascular calcification, were independently
ssociated with death both in patients with previous myo-
ardial infarctions and in the general population (38).
enetic markers. The field of genetics was particularly
ctive in 2009. Variants of the ABCB1 and CYP2C19 alleles,
nvolved in the absorption and metabolic activation of
lopidogrel, respectively, were independently associated
ith a higher risk for 1-year mortality, nonfatal myocardial
nfarction, or stroke in 2,200 infarct survivors receiving
his therapy (39). In contrast, similar genetic variants of
ytochrome P450 activity did not affect drug action or event
ates in persons treated with prasugrel (40). A study involv-
ng 11,550 patients and 11,205 controls confirmed the link
etween the 9p21.3 locus and CHD risk and replicated
ssociations of 3 other loci also identified in prior studies
41). The 9p21.3 region was shown to contain an enhancer
hat regulates the expression of genes involved in cellular
roliferation, providing a possible mechanistic link for
ncreased atherosclerosis in carriers of the risk allele (42).
owever, the addition of knowledge of 9p21.3 carrier status
o 22,000 white participants in the Women’s Health
tudy did not provide additive prognostic value to conven-
ional risk stratification (43). Finally, genome-wide associ-
tion studies combining data from 4 prospective
opulation-based cohorts identified mildly increased risk for
therothrombotic stroke in carriers of chromosome 12p13
ariants (44).
nvasive imaging. Pooled data from 7 intravascular ultra-
ound (IVUS) studies in patients with established CHD
evealed that both very low LDL cholesterol (70 mg/dl)
nd low systolic blood pressure (120 mm Hg) are associ-
ted with slower progression of coronary atherosclerosis
45). A large registry of almost 1,000 patients who under-
ent IVUS and virtual histology reported larger necrotic
ores in association with age, diabetes mellitus, hyperten-
ion, and low high-density lipoprotein (HDL) cholesterol
46). The presence of multiple plaques with features of
ulnerability in nontarget vessels as detected with coronary
VUS may have prognostic implications, according to a
tudy in 183 patients with CHD (47). These findings are
lso relevant in view of the significant estimated prevalence
f high-risk, nonstenotic coronary plaques in 50% of
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Year in Atherothrombosis April 6, 2010:1487–98iddle-age, apparently healthy subjects (48). Similar poten-
ial prognostic value for the use of IVUS with virtual
istology was reported in the PROSPECT (Providing
egional Observations to Study Predictors of Events in the
oronary Tree) trial. A thin fibrous cap, a minimum lumen
4.0 mm2, and a plaque burden 70% were predictors of
he 3-year lesion-related incidence of events (49).
Studies using optical coherence tomography additionally
rovided important insights into the physiopathology of
HD. It was suggested that thin fibrous caps can rupture
oth at rest and with exercise, whereas some thick fibrous
ap lesions may also rupture in relation to exertion (50).
oreover, an inverse correlation was described between
brous cap thickness and plasma levels of inflammatory
arkers, including CRP, interleukin-18, tumor necrosis
actor-alpha, and peripheral white blood cell counts (51).
inally, a catheter-based near-infrared spectroscopy system
as validated for detection of coronary lipid-rich plaques in
ivo (Fig. 3) (52).
oninvasive imaging. Data from a large randomized trial
f antihypertensive therapy replicated the independent as-
ociation of CIMT with cardiovascular prognosis; however,
he investigators questioned the value of using it as an end
oint in the evaluation of atheroprotective therapy, as
IMT changes were not predictive of outcomes (53). In
ivo contrast enhancement of human carotid plaques eval-
ated with ultrasound was used to study the degree of
Figure 3 Near-Infrared Spectroscopy
(Top) Invasive angiogram of the right coronary artery of a patient with unstable an
ing near-infrared spectroscopy (NIRS) scan revealing prominent lipid content at the
mal” proximal segment (A). Prob  probability. Reproduced, with permission, fromeovascularization. The incidence of enhancement and the
atio of plaque to luminal enhancement were more
ronounced in patients with symptomatic cerebrovascular
isease (54). Reinforcing the importance of long-term
ardiovascular risk, a study measuring CIMT and coro-
ary artery calcium (CAC) in subjects with low 10-year
isk by the National Cholesterol Education Program
dult Treatment Panel III demonstrated a higher ath-
rosclerotic burden and faster progression in those with
igh lifetime risk (55).
A report from the MESA study indicated that absolute
AC scores predict CHD better than age-, gender-, or
thnicity-adjusted percentiles (56). A study including over
4,000 asymptomatic subjects confirmed the excellent prog-
osis associated with absent CAC, with a 10-year mortality
f 1%, whereas minimal CAC (Agatston score: 1 to 10)
oubles the risk (57). This year there was more evidence of
he utility of noninvasive plaque imaging with contrast-
nhanced computed tomography (CT). A registry of 432
atients identified noncalcified coronary plaque as a predic-
or of outcomes with incremental value over the calcium
core (58). In an important investigation including 1,000
ubjects undergoing coronary CT angiography, the presence
f 2 features of plaque vulnerability (positive remodeling
nd low attenuation suggestive of a lipid-rich core) (Fig. 4)
ere strongly associated with same-site development of
cute coronary syndromes during the next 2 years (hazard
howing a complex culprit lesion in the mid segment (B). (Bottom) Correspond-
of the culprit stenosis (B) and another lipid-rich area in an “angiographically nor-
an et al. (52).gina, s
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April 6, 2010:1487–98 Year in Atherothrombosisatio: 22.8; p 0.001) (59). The feasibility of studying serial
hanges in plaque burden with CT was also reported in an
xperimental atherosclerosis model (60). Combining CT
nd positron emission tomography, vascular calcification
nd inflammation were shown to rarely coexist (Fig. 5),
upporting the notion that calcification represents a healing
esponse in atherosclerosis. Moreover, inflammation was
Figure 4 Coronary CT Angiogram of Noncalcified Plaques
Contrast-enhanced computed tomography (CT) angiogram of the left anterior desce
large noncalcified plaque with low attenuation and marked positive remodeling in t
head). The patient presented 6 months later with an acute coronary syndrome. An
plaque (upper black arrow) and confirmed the LCX lesion (lower black arrow). Mo
Figure 5 Imaging of Vascular Inflammation
Computed tomography (A), positron emission tomography (B), and fused images
sis. Computed tomography demonstrates absent calcification in the ascending aor
However, there is marked inflammation in the ascending aorta (B) (green arrow) a
from Rudd et al. (61).orrelated directly to serum matrix metalloproteinase levels
nd inversely to adiponectin concentrations (61).
A magnetic resonance imaging (MRI) study in asymp-
omatic men with moderate carotid stenosis indicated that
ntraplaque hemorrhage predicted cerebrovascular events
ithin 2 years (62). Intraplaque hemorrhage and a large
ipid core were also independently associated with thin
coronary artery (LAD) (A) and left circumflex coronary artery (LCX) (B). There is a
ximal LAD (white arrow) and a significant stenosis in the LCX (white arrow-
ive angiogram (C) identified the culprit lesion at the level of the proximal LAD
, with permission, from Motoyama et al. (59).
oth techniques (C) depicting the aorta of a patient with systemic atherosclero-
significant calcium in the infrarenal abdominal segment (A) (green arrows).
le in the abdominal portion (B) (green arrows). Reproduced, with permission,nding
he pro
invas
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Year in Atherothrombosis April 6, 2010:1487–98nd/or ruptured fibrous caps (63). A substudy of the MESA
emonstrated the feasibility of quantifying coronary wall
emodeling in asymptomatic subjects with MRI (64).
oreover, the plaque characterization capabilities of MRI
ere also explored in the coronary tree (65).
olecular imaging. Ultrasmall superparamagnetic iron
xide particles, an MRI contrast agent that is taken up by
acrophages, were used to successfully track reductions in
uman carotid inflammation with high-dose statin therapy
66). Similar findings were reported for matrix metallopro-
einase activity in an experimental model of atherosclerosis
ith a technetium-99m–labeled tracer (67). The change in
RI signal intensity associated with plaque uptake of
adofluorine M in a rabbit model of atherosclerosis was
ignificantly higher in advanced plaques compared with
arly atheroma and was correlated with the degree of
eovascularization and inflammation (68). Gadolinium-
oaded lipid-based nanoparticles targeted to the macrophage
cavenger receptor were shown to improve the detection of
nflammation in human carotid artery specimens (69).
nother aspect of inflammation, the expression of endothe-
ial vascular cell adhesion molecule-1, was evaluated using a
adiolabeled tracer and positron emission tomography (70).
ome studies explored the potential of molecular techniques
ot only for diagnosis but also for the delivery of therapy.
lycoprotein IIb/IIIa–targeted microbubbles coupled with
igh-mechanical index ultrasound led to improvements in
oth coronary patency and microvascular perfusion in a
orcine model of myocardial infarction (71). In addition,
xternal guidance of magnetically labeled endothelial pro-
enitor cells enhanced their delivery to sites of experimental
rterial injury (72).
The role of different invasive and noninvasive modalities
n the evaluation of plaque characteristics (Fig. 6) was
legantly reviewed elsewhere (73).
Figure 6 Techniques for Plaque Imaging
Techniques for plaque imaging. Reproduced, with permission, from Matter et al. (7
FeOx  iron oxide; Fluo  fluorescence imaging; IVUS  intravascular ultrasound;
optical frequency domain imaging; PET  positron emission tomography; VCAM revention and Treatment
he long-term benefits of lifestyle choices were revisited in
lmost 75,000 women followed for 20 years: greater adher-
nce to the Mediterranean diet was independently associ-
ted with lower CHD and stroke incidence (74). According
o a meta-analysis of 11 trials, banning public smoking is
ssociated with a 17% reduction of myocardial infarction
ncidence, an effect greater for the young and nonsmokers
75). The importance of primary prevention was reinforced
y a registry showing that the 3-year incidence of vascular
eath, myocardial infarction, or stroke is 12% for patients
ith established atherothrombotic disease and 6% for pa-
ients with 3 risk factors (76). These data were derived
rom a population with a relatively high use of modern
econdary prevention therapies; however, a study from the
.S. found that only 30% to 60% of patients with CHD
eceive appropriate treatment (77). The pharmacodynamic
ffects of a once-daily polypill containing aspirin (100 mg),
imvastatin (20 mg), thiazide (12.5 mg), atenolol (50 mg),
nd ramipril (5 mg) were tested in a multicenter primary
revention study performed in India. After 12 weeks of
ctive therapy, the polypill was as effective as the individual
omponents in decreasing blood pressure and slowing heart
ate, with slightly less (although still substantial) lipid-lowering
nd platelet inhibitor effects. The investigators estimated that
he reductions in risk factors observed would potentially de-
rease incident CHD by 62% and stroke by 48% (78).
The importance of intensive medical therapy was empha-
ized in subanalyses of the COURAGE (Clinical Outcomes
tilizing Revascularization and Aggressive Drug Evalua-
ion) trial. In stable CHD, it proved as beneficial as
evascularization in elderly patients (79) or in those with
igh-risk features (80), although at the expense of high
rossover rates in the medical therapy arm. The BARI 2D
 computed tomography; ED-B  extradomain B; FDG  fluorodeoxyglucose;
magnetic resonance imaging; OCT  optical coherence tomography; OFDI 
lar cell adhesion molecule; VEGF  vascular endothelial growth factor.3). CT
MRI 
vascu
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April 6, 2010:1487–98 Year in AtherothrombosisBypass Angioplasty Revascularization Investigation 2 Di-
betes) trial randomized 2,368 patients with type 2 diabetes
nd proven obstructive CHD to intensive medical therapy
ith or without early revascularization (81). The revascu-
arization strategy (percutaneous or surgical) was chosen by
he treating physician as the most appropriate. Therefore,
nd not surprisingly, patients referred for surgery had more
xtensive disease than those referred for percutaneous inter-
ention. Overall, there were no differences in 5-year survival
ates between the medical therapy group and the revascu-
arization group (87.8% vs. 88.3%, respectively; p  0.97).
imilar results were found for the incidence of a composite
Figure 7 Summary Results of the BARI 2D Trial
Rates of survival (A, B) and freedom from major cardiovascular events (defined as
revascularization in the BARI (Bypass Angioplasty Revascularization Investigation 2
artery bypass grafting; PCI  percutaneous coronary intervention.nd point of death, myocardial infarction, or stroke (24.1%
nd 22.8%, respectively; p  0.70), although 42% of
atients initially treated medically required revascularization
n follow-up. In those patients in whom surgical interven-
ion was considered most appropriate, revascularization
educed the risk for subsequent nonfatal events in compar-
son with medical therapy (Fig. 7). These findings resemble
hose previously reported in the context of surgical versus
ercutaneous revascularization in the SYNTAX (Synergy
etween PCI With Taxus and Cardiac Surgery) trial (82).
yslipidemia. LDL cholesterol continues to be the first
herapeutic target in atherothrombotic disease, and data
, myocardial infarction, or stroke) (C, D) for patients treated medically or with
tes) trial. Reproduced, with permission, from Frye et al. (81). CABG  coronarydeath
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Year in Atherothrombosis April 6, 2010:1487–98rom 20,000 male subjects demonstrated that the largest
ardiovascular benefits derive from most pronounced reduc-
ions in LDL levels, regardless of age (83). In addition,
urther support for the National Cholesterol Education
rogram Adult Treatment Panel III recommendation to use
on-HDL cholesterol as a secondary goal for treatment
ame from a meta-analysis of 30 trials (84). The potential of
DL as an additional therapeutic target was highlighted in
he Framingham Offspring study. Long-term follow-up
emonstrated that increases in HDL cholesterol with lipid-
owering therapy were independently associated with im-
roved cardiovascular outcomes (85). This was further
upported by 16-year follow-up data from the BIP (Beza-
brate Infarction Prevention) trial, which demonstrated
ignificant reductions in mortality for patients with CHD
ho achieved the largest increases in HDL concentrations
86). Modified-release nicotinic acid therapy for 12 months
aused a regression of carotid and aortic atherosclerosis by
RI in statin-treated patients with low HDL cholesterol
87). In another randomized trial in patients with CHD or
HD equivalent, extended-released niacin also caused a
mall (although statistically significant) CIMT regression
88). Moreover, reconstituted HDL infusion demonstrated
ntithrombotic effects by attenuating platelet hyperreactivity
n subjects with type 2 diabetes (89).
CRP may constitute a nonlipid target to guide statin
herapy. Data from the JUPITER trial indicated that
linical benefit derived from rosuvastatin 20 mg/day versus
lacebo in apparently healthy subjects was highest in pa-
ients in whom both LDL cholesterol and CRP levels were
educed by therapy. Regardless of the LDL concentration
owering reached, benefit was higher across decreasing strata
f achieved CRP levels (Fig. 8) (90). On the basis of the
revalence of low LDL but high CRP levels, it was
stimated that in the U.S., approximately 6.5 million adults
ould be candidates for statin therapy (91) and that on the
asis of CRP alone, the percentage of elderly patients
Figure 8 Cardiovascular Risk and hsCRP and LDL Levels
Multivariate-adjusted hazard ratios for incident cardiovascular events (expressed p
(LDL) cholesterol and high-sensitivity C-reactive protein (hsCRP) in the JUPITER (Ju
Rosuvastatin) study. Reproduced, with permission, from Ridker et al. (90).equiring statins would increase from 35% to 68% (92).
leiotropic effects of statin therapy were also addressed in
UPITER, where the risk for venous thromboembolic
vents was halved in those receiving rosuvastatin (93).
Additionally, previous observational evidence regarding
he potential benefits of statin therapy in patients with
hronic kidney disease was not replicated in a large, multi-
enter trial that randomized 2,776 patients on hemodialysis,
ith and without known cardiovascular disease, to rosuvas-
atin 10 mg/day or placebo. After a mean follow-up of 3.8
ears and despite significant reductions in LDL cholesterol
nd CRP levels, statins were not associated with different
ates of cardiovascular morbidity or mortality (94).
ypertension. A multicenter trial performed in Italy
ncluding 1,100 patients without diabetes proposed a
arget systolic blood pressure of 130 mm Hg in this
opulation because of a significant reduction in the rate
f left ventricular hypertrophy and a combined cardio-
ascular end point at 2 years in comparison with the
tandard target of 140 mm Hg (95). The ACCOM-
LISH (Avoiding Cardiovascular Events Through Com-
ination Therapy in Patients Living With Systolic Hy-
ertension) trial randomized 11,506 patients with
ypertension and high cardiovascular risk (defined as
iabetes, renal failure, or prior cardiovascular disease) to
enazepril plus either amlodipine or hydrochlorothiazide.
he average blood pressures achieved were 131.6/73.3
nd 132.5/74.4 mm Hg, respectively (p  0.001). The
tudy was stopped prematurely after 3 years because of
arked reductions (hazard ratio: 0.80; p  0.001) in the
rimary end point of cardiovascular death plus a combi-
ation of cardiovascular events in the arm receiving the
alcium-channel blocker (96). Conversely, a reanalysis of
ata from the ALLHAT (Antihypertensive and Lipid-
owering Treatment to Prevent Heart Attack Trial) sup-
orted the use of thiazide diuretics as the first-line therapy
or treating hypertension because of favorable effects on
person-years) according to achieved concentrations of low-density lipoprotein
ion for the Use of Statins in Primary Prevention: An Intervention Trial Evaluatinger 100
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April 6, 2010:1487–98 Year in Atherothrombosisardiovascular outcomes, particularly in reducing heart fail-
re, in comparison with other antihypertensive classes (97).
iabetes. Patients with diabetes in the Framingham Heart
tudy experienced decreases in all-cause and cardiovascular
ortality during the past 50 years, although they remain at
igher risk than patients without diabetes (98). These
eductions appear to be largely dependent on aggressive
reatment of conventional risk factors (99), whereas the role
f intensive glycemic control in the risk for macrovascular
omplications has remained controversial.
The VADT (Veterans Affairs Diabetes Trial) random-
zed 1,791 patients with poorly controlled type 2 diabetes to
tandard or intensive glucose-lowering therapy. After a
edian follow-up period of 5.6 years, the study failed to
how benefits of intensive therapy for any macrovascular
utcome (100). In contrast, long-term (20-year) follow-up
f a smaller study demonstrated lower risk for CHD in
atients with diabetes with decreasing levels of glycosylated
emoglobin (101). Moreover, a meta-analysis of 5 prospec-
ive randomized trials including 33,000 participants iden-
ified associations of intensive glucose-lowering regimens
overall glycosylated hemoglobin level: 6.6% vs. 7.5%) with
15% reduction in CHD events (Fig. 9) but no significant
hanges in stroke or overall mortality (102). In a joint
osition statement, the American Diabetes Association, the
merican Heart Association, and the American College of
ardiology continued to endorse the current target of
lycosylated hemoglobin 7%, as there is clear evidence
hat it leads to reductions in microvascular complications. Such
target may also lead to decreased macrovascular disease,
erhaps later in life (a IIb recommendation). More aggressive
herapy may be beneficial in patient subgroups (such as those
ith shorter duration of diabetes or no known cardiovascular
isease) but detrimental in others (i.e., those with long-term
iabetes, advanced cardiovascular disease, or histories of severe
ypoglycemia) (103). Regarding specific therapies, the BARI
Figure 9 Intensive Versus Standard Glucose-Lowering Therapy
Meta-analysis of the probability of coronary heart disease events with intensive ve
Ray et al. (102). ACCORD  Action to Control Cardiovascular Risk in Diabetes; AD
trolled Evaluation; CI  confidence interval; PROactive  Prospective Pioglitazone
Study; VADT  Veterans Affairs Diabetes Trial.D trial did not find different cardiovascular outcomes with
nsulin provision versus insulin sensitization (81).
ntithrombotic therapy. A meta-analysis of the use of
spirin for primary (6 trials, 95,000 subjects) or secondary
16 trials, 17,000 subjects) cardiovascular prevention re-
orted associations of conventional risk factors with the
robability of adverse events and questioned its widespread
se in patients without previous cardiovascular disease, even
ith moderate baseline risk (104). Another meta-analysis
aised similar doubts about aspirin use for secondary pre-
ention in patients with established peripheral arterial dis-
ase (105). A prospective study including 500 patients
ith noncardioembolic ischemic stroke and no significant
arotid stenoses evaluated the pathogenic role of aortic arch
therosclerosis. Large and complex aortic plaques (present
n almost 20% of the patients) independently doubled the
-year incidence of recurrent stroke or death, without
ifferences between patients treated with either warfarin or
spirin (106). Finally, in patients with acute coronary
yndromes, the PLATO (Platelet Inhibition and Patient
utcomes) study tested the effects of dual-antiplatelet
herapy with aspirin and ticagrelor, a novel short-acting
denosine diphosphate receptor antagonist that, as opposed
o clopidogrel, does not require metabolic conversion and
as more potent inhibitory properties. The study random-
zed 18,000 patients with acute coronary syndromes (with
nd without ST-segment elevation) to aspirin plus either
lopidogrel or ticagrelor for 12 months. Ticagrelor signifi-
antly reduced cardiovascular outcomes during follow-up
Fig. 10), without overall increases in major bleeding,
lthough there was an increase in non-procedure-related
emorrhage (107). Two recent randomized trials tested the
linical utility of another short-acting, reversible adenosine
iphosphate receptor antagonist, cangrelor. Both studies
howed that cangrelor was not superior to the established use
f clopidogrel in reducing periprocedural events in patients
betes
tandard glucose-lowering therapy in 5 trials. Reproduced, with permission, from
 Action in Diabetes and Vascular Disease: Preterax and Diamicron-MR Con-
l Trial in Macrovascular Events; UKPDS  United Kingdom Prospective Diabetesin Dia
rsus s
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inally, although not specifically tested in atherothrombotic
isease, oral direct thrombin inhibitors represent a novel
romising approach to antithrombotic therapy (110).
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